**Supplementary Table 1. Nomenclature and reference ranges of the TEG and Sonoclot instruments**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **TEG** | **Range** | **Sonoclot** | **Range** | **Factors affecting clot formation** | **Therapeutic options** |
| Clotting time: time to 2 mm amplitude | R | 4-8 m | Son-ACT | 85-145 sec | Factors XII and X1 activity; reflective of intrinsic pathway if activators not used | Administration of plasma, coagulation factors, fibrinogen or platelets |
| Clot kinetics: time from 2 to 20mm clot firmness | K | 1-4 m |   |   | Factors II and VIII activity; platelet count and function, thrombin, fibrinogen, HCT |
| Rate of fibrin formation/ clot kinetics | Alpha angle |  47-74 ° | CR R1 | 15-45 clot signal U/m | Factors II and VIII activity; platelet count and function, thrombin, fibrinogen, HCT |  |
| Clot strength | MA  | 55-73mm |   |   | Fibrinogen, platelet count and function, thrombin, factor XIII activity, HCT |   |
| Index of fibrinogen conversion to fibrin |   |   | Time to peak | 540-600 s |   |   |
| Platelet-induced clot retraction | CL30, CL45, CL60 |   | R3 | >2 mm/m |   | Antifibrinolytic drugs and additional measures, such as administration of fibrinogen or platelets |

Abbreviation: HCT, Hematocrit.